Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic polymorphisms in diabetic nephropathy and efficacy of SGLT2 inhibitors
ChiCTR2200066653Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin and canagliflozin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Urinary microalbumin creatinine ratio. Started Sep 2022; status: recruiting.
02
Drugs
dapagliflozincanagliflozin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200066653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066653.